An independent two-stage DCF analysis by a frontier AI model.
Bio-Techne represents a classic 'picks and shovels' investment in the biopharma space. Rather than taking on the massive clinical and regulatory risks associated with drug development, the company provides the essential tools, proteins, and instruments that enable that research.
The company's transition from a pure reagent provider to a broader platform company offering complex analytical instruments has expanded its addressable market and entrenched it deeper within customer workflows. While currently trading near its calculated fair value, its high-margin recurring revenue model and strong execution track record make it an attractive asset for long-term compound growth.
An 8% FCF growth rate is projected. Bio-Techne operates in high-growth segments of the life sciences market, benefiting from recurring reagent revenues and increasing adoption of its diagnostic tools. However, current macroeconomic pressures on biotech funding temper slightly higher historical growth rates.
An 8.5% discount rate reflects the relative stability of its recurring revenue streams from research consumables, offset by the inherent volatility of smaller-cap growth stocks in the healthcare sector.
A 3% terminal growth rate assumes Bio-Techne will continue to grow slightly faster than general GDP over the long term, driven by sustained, structural increases in global healthcare and biopharma R&D spending.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 2.0% | $58.91 | $48.20 | $40.78 | $35.35 | $31.19 |
| 2.5% | $66.28 | $53.02 | $44.18 | $37.87 | $33.14 |
| 3.0% | $75.74 | $58.91 | $48.20 | $40.78 | $35.35 |
| 3.5% | $88.37 | $66.27 | $53.02 | $44.18 | $37.87 |
| 4.0% | $106.04 | $75.74 | $58.91 | $48.20 | $40.78 |
■ Undervalued vs current price ■ Overvalued vs current price
Bio-Techne is positioned in fast-growing sectors like spatial biology and gene therapy tools. While long-term trends are strong, an 8% rate balances this optimism against near-term constraints in academic and biotech venture funding.
The rate balances the high predictability of its consumable reagent sales (which act almost like an annuity) against the broader market risks associated with growth-oriented healthcare valuations.
Based on this model, the stock is currently trading within the range of fair value. It rarely trades at a deep discount due to its high-quality business model and recurring revenue base.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.